All GSK articles
-
NewsCARB‑X–supported trivalent Salmonella vaccine advances to Phase 2 clinical trials
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) today announced that GSK’s global health vaccine program for a combined invasive nontyphoidal Salmonella and typhoid fever (iNTS‑TCV) has advanced into a Phase 2 clinical trial.
-
NewsGSK and Fleming Initiative scientists unite to target AMR with advanced AI
GSK and the Fleming Initiative have announced six major new research programmes, called ‘Grand Challenges’ which harness some of the best scientific expertise and the latest technologies, including advanced AI, to find new ways to slow the progress of antimicrobial resistance (AMR).
-
NewsScientists design new drug to fight malaria
Scientists have designed a new drug against malaria and identified its mechanism of action. MED6-189 is effective against drug-sensitive and drug-resistant P. falciparum strains in vitro as well as in a humanized mouse model.